Developer of anticancer and anti inflammation drugs intended to treat chronic inflammatory diseases. The company's drugs are researched for the treatment of cystic fibrosis, a disease that predominantly affects the lungs and is inline to create medication for the cure of chronic obstructive pulmonary diseases and allergic asthma, enabling patients with a treatment for their incurable respiratory diseases.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
2. Later Stage VC (Series A) | 26-Jul-2019 | $6.35M | 00.000 | 000.00 | Completed | Generating Revenue |
1. Accelerator/Incubator | Completed | Startup |
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series A | 00,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 00.000 |
Name | Representing | Role | Since |
---|---|---|---|
Laura Ferro | Self | Chairman | 000 0000 |
Pietro Puglisi | Claris Ventures | Board Member | 000 0000 |
Svetlana Vashkel | CDP Venture Capital | Board Member | 000 0000 |
Vincent Metzler Ph.D | Self | Board Member | 000 0000 |
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Ace Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
B-Engine | Venture Capital | Minority | 000 0000 | 000000 0 | |
CDP Venture Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
Claris Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
Club degli investitori | Angel Group | Minority | 000 0000 | 000000 0 |